Clinical Trial Update: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

SCG101 is being studied in a Phase 1/2 trial for hepatitis B virus-related hepatocellular carcinoma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SCG101

Snippet

Sponsor: SCG Cell Therapy Pte. Ltd. | Conditions: Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma Recurrent | Phase 1, Phase 2 | Status: RECRUITING